X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5161) 5161
Newsletter (151) 151
Newspaper Article (46) 46
Magazine Article (13) 13
Book Chapter (4) 4
Conference Proceeding (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (3827) 3827
life sciences & biomedicine (3664) 3664
humans (3297) 3297
niacinamide - analogs & derivatives (2810) 2810
male (2621) 2621
animals (2253) 2253
female (1883) 1883
niacinamide (1539) 1539
niacinamide - administration & dosage (1447) 1447
oncology (1323) 1323
middle aged (1265) 1265
sorafenib (1128) 1128
aged (1056) 1056
niacinamide - pharmacology (990) 990
niacinamide - therapeutic use (977) 977
adult (941) 941
rats (931) 931
phenylurea compounds (911) 911
mice (848) 848
treatment outcome (820) 820
antineoplastic agents - therapeutic use (702) 702
pharmacology & pharmacy (699) 699
phenylurea compounds - administration & dosage (675) 675
liver neoplasms - drug therapy (659) 659
carcinoma, hepatocellular - drug therapy (639) 639
cancer (585) 585
analysis (551) 551
phenylurea compounds - therapeutic use (529) 529
care and treatment (519) 519
research (515) 515
nicotinamide (507) 507
antineoplastic agents - administration & dosage (500) 500
hepatocellular carcinoma (465) 465
niacinamide - adverse effects (462) 462
pyridines - administration & dosage (456) 456
antineoplastic agents (450) 450
benzenesulfonates - administration & dosage (432) 432
dose-response relationship, drug (432) 432
antimitotic agents (431) 431
pyridines - therapeutic use (425) 425
kidney neoplasms - drug therapy (420) 420
carcinoma, renal cell - drug therapy (419) 419
liver neoplasms - pathology (415) 415
aged, 80 and over (409) 409
cell line, tumor (407) 407
antineoplastic combined chemotherapy protocols - therapeutic use (406) 406
benzenesulfonates - therapeutic use (403) 403
carcinoma, hepatocellular - pathology (398) 398
antineoplastic agents - adverse effects (396) 396
protein kinase inhibitors - therapeutic use (351) 351
phosphates (349) 349
phenylurea compounds - adverse effects (343) 343
liver cancer (342) 342
apoptosis (333) 333
drug therapy (333) 333
time factors (314) 314
disease-free survival (309) 309
medicine & public health (302) 302
administration, oral (300) 300
abridged index medicus (296) 296
apoptosis - drug effects (294) 294
rats, wistar (293) 293
hepatoma (292) 292
disease models, animal (289) 289
physiological aspects (289) 289
health aspects (278) 278
tumors (274) 274
phenylurea compounds - pharmacology (268) 268
protein kinase inhibitors - administration & dosage (268) 268
retrospective studies (266) 266
pyridines - adverse effects (265) 265
neurosciences & neurology (261) 261
oxidative stress (261) 261
benzenesulfonates - adverse effects (259) 259
chemotherapy (258) 258
neurosciences (256) 256
antineoplastic agents - pharmacology (255) 255
rats, sprague-dawley (255) 255
rodents (255) 255
metastasis (253) 253
purines (252) 252
prognosis (247) 247
cell biology (244) 244
gastroenterology & hepatology (241) 241
kidney neoplasms - pathology (240) 240
cell proliferation - drug effects (239) 239
biochemistry & molecular biology (223) 223
neoplasm staging (222) 222
diabetes (220) 220
digestive system diseases (217) 217
neoplasms (215) 215
protein kinase inhibitors - adverse effects (213) 213
proteins (213) 213
indoles - administration & dosage (212) 212
kinases (212) 212
pyridines - pharmacology (209) 209
vascular endothelial growth factor (209) 209
drug administration schedule (205) 205
enzymes (205) 205
liver (205) 205
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5116) 5116
Russian (175) 175
Japanese (109) 109
German (64) 64
French (23) 23
Chinese (20) 20
Italian (15) 15
Ukrainian (9) 9
Spanish (8) 8
Polish (7) 7
Portuguese (5) 5
Bulgarian (4) 4
Danish (2) 2
Hungarian (2) 2
Slovak (2) 2
Czech (1) 1
Dutch (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of clinical oncology, ISSN 0732-183X, 11/2012, Volume 30, Issue 32, pp. 4017 - 4025
Therapeutic drug monitoring (TDM) provides valuable guidance for dose adjustment of antibiotics, immunosuppressives, antiepileptics, and other drugs, but its... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Neoplasms - metabolism | Niacinamide - analogs & derivatives | Piperazines - administration & dosage | Thiazoles - blood | Injections, Intravenous | Area Under Curve | Pyrimidines - blood | Humans | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Half-Life | Thiazoles - administration & dosage | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Drug Monitoring - methods | Indoles - administration & dosage | Antibodies, Monoclonal - blood | Antibodies, Monoclonal, Humanized | Neoplasms - blood | Antineoplastic Agents - adverse effects | Pyrroles - administration & dosage | Benzenesulfonates - blood | Antineoplastic Agents - pharmacokinetics | Cetuximab | Piperazines - blood | Everolimus | Molecular Targeted Therapy - methods | Dasatinib | Sirolimus - analogs & derivatives | Pyridines - administration & dosage | Pyrimidines - administration & dosage | Indoles - blood | Rituximab | Pyrroles - blood | Sirolimus - blood | Evidence-Based Medicine | Imatinib Mesylate | Neoplasms - drug therapy | Sirolimus - administration & dosage | Antibodies, Monoclonal, Murine-Derived - blood | Pyridines - blood | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - blood | Benzamides | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 05/2016, Volume 387, Issue 10032, pp. 2008 - 2016
Journal Article
Journal Article
Journal Article
Cancer Letters, ISSN 0304-3835, 2012, Volume 320, Issue 1, pp. 104 - 110
Abstract Molecularly targeted therapies have emerged as the leading theme in cancer therapeutics. Multi-cytotoxic drug regimens have been highly successful,... 
Hematology, Oncology and Palliative Medicine | Combination index | Dasatinib | Molecular targeted therapy | Rapamycin | Life Sciences & Biomedicine | Oncology | Science & Technology | Niacinamide - analogs & derivatives | Paclitaxel - pharmacology | Nitriles - pharmacology | Humans | Epothilones - pharmacology | Thiazoles - administration & dosage | Chromones - administration & dosage | Phenylurea Compounds | Benzenesulfonates - administration & dosage | Tamoxifen - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Benzenesulfonates - pharmacology | Female | Chromones - pharmacology | Paclitaxel - administration & dosage | Butadienes - pharmacology | Pyridines - administration & dosage | Pyrimidines - administration & dosage | Morpholines - administration & dosage | Enzyme Inhibitors - pharmacology | Morpholines - pharmacology | Pyrimidines - pharmacology | Breast Neoplasms - drug therapy | Sirolimus - pharmacology | Drug Synergism | Sirolimus - administration & dosage | Signal Transduction - drug effects | Butadienes - administration & dosage | Epothilones - administration & dosage | Tamoxifen - pharmacology | Cell Line, Tumor | Pyridines - pharmacology | Thiazoles - pharmacology | Care and treatment | Oncology, Experimental | Genes | Breast cancer | Research | Tamoxifen | Cancer | Index Medicus
Journal Article
Annals of oncology, ISSN 0923-7534, 01/2014, Volume 25, Issue 1, pp. 149 - 154
Journal Article
Annals of oncology, ISSN 1569-8041, 11/2012, Volume 23, Issue 11, pp. 2799 - 2805
Sorafenib is an oral anticancer agent targeting Ras-dependent signaling and angiogenic pathways. A phase I trial demonstrated that the combination of... 
phase III randomized trial | gemcitabine | sorafenib | advanced pancreatic cancer | Advanced pancreatic cancer | Gemcitabine | Sorafenib | Phase III randomized trial | Life Sciences & Biomedicine | Oncology | Science & Technology | Niacinamide - analogs & derivatives | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Antimetabolites, Antineoplastic - administration & dosage | Pancreatic Neoplasms - drug therapy | Deoxycytidine - therapeutic use | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Aged, 80 and over | Placebos | Adult | Deoxycytidine - adverse effects | Female | Double-Blind Method | Deoxycytidine - administration & dosage | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Niacinamide - administration & dosage | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Antimetabolites, Antineoplastic - therapeutic use | Phenylurea Compounds - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Ribonucleotide Reductases - antagonists & inhibitors | Antimetabolites, Antineoplastic - adverse effects | Aged | Deoxycytidine - analogs & derivatives | Index Medicus
Journal Article
European journal of cancer (1990), ISSN 0959-8049, 03/2013, Volume 49, Issue 5, pp. 1027 - 1031
Abstract Background Tyrosine kinase inhibitors (TKI) improve the outcome of patients with advanced gastrointestinal stromal tumour (GIST), but treatment... 
Hematology, Oncology and Palliative Medicine | Nilotinib | Progression | GIST | Sunitinib | Imatinib | Relapse | Salvage | Tyrosine kinase inhibitor | Sorafenib | Gastrointestinal stromal tumour | Life Sciences & Biomedicine | Oncology | Science & Technology | Niacinamide - analogs & derivatives | Piperazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Gastrointestinal Neoplasms - drug therapy | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Dose-Response Relationship, Drug | Young Adult | Gastrointestinal Neoplasms - pathology | Phenylurea Compounds - adverse effects | Pyrroles - administration & dosage | Gastrointestinal Stromal Tumors - pathology | Aged, 80 and over | Pyrroles - adverse effects | Adult | Female | Retrospective Studies | Chemotherapy, Adjuvant | Drug Administration Schedule | Pyrimidines - administration & dosage | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Imatinib Mesylate | Piperazines - adverse effects | Disease Progression | Niacinamide - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Indoles - adverse effects | Phenylurea Compounds - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Gastrointestinal Stromal Tumors - drug therapy | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - adverse effects | Aged | Benzamides | Antimitotic agents | Medical colleges | Care and treatment | Sarcoma | Analysis | Antineoplastic agents | Phosphotransferases | Index Medicus
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2013, Volume 40, Issue 2, pp. 271 - 275
Journal Article